Starpharma sees impressive new data published

Company News

by Rachael Jones

Pharmaceutical Starpharma (ASX:SPL) today announced impressive data from AstraZeneca published by the World Intellectual Property Organisation.

The patent for Starpharma’s DEP delivery technology with AstraZeneca’s inhibitor is highly effective across a range of cancer types including leukemias.

Starpharma CEO, Dr Jackie Fairley says the combination with blockbuster products shows a strong synergy, also with other leading anti-cancer drugs and that this could represent an important additional benefit for the DEP platform.

Shares in Starpharma (ASX:SPL) are trading 12.17 per cent higher to $1.29.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.